Transplantation Direct (Jul 2022)

Long-term Survival Following Heart Transplantation for Chagas Versus Non-Chagas Cardiomyopathy: A Single-center Experience in Northeastern Brazil Over 2 Decades

  • Jefferson L. Vieira, MD, MBA, PhD,
  • Maria G. V. Sobral, RN,
  • Francisco Y. Macedo, MD, PhD,
  • Raquel S. Florêncio, RN,
  • Germana P. L. Almeida, MD,
  • Glauber G. Vasconcelos, MD,
  • Juliana R. Fernandes, MD,
  • Laura L. E. Marinho, MD,
  • Daniel F. M. Trompieri, MD,
  • Tilak K. R. Pasala, MD,
  • Juan A. C. Mejia, MD,
  • João D. Souza-Neto, MD, PhD

DOI
https://doi.org/10.1097/TXD.0000000000001349
Journal volume & issue
Vol. 8, no. 7
p. e1349

Abstract

Read online

Background. Data on post–heart transplant (HT) survival of patients with Chagas cardiomyopathy (CC) are scarce. We sought to evaluate post-HT survival in patients with CC as compared with other causes of heart failure across different eras of HT. Methods. We conducted a retrospective, cohort study of 376 adult HT recipients between October 1997 and November 2019. Participants were classified according to the etiology of heart failure as CC (N = 66), nonischemic cardiomyopathy (N = 214), and ischemic cardiomyopathy (N = 96), and according to the era of HT as early (1997–2009), recent (2010–2014), and current era (2015–2019). Results. After a mean follow-up of 5.0 y (0–20.5 y), post-HT survival rates at 1, 5, and 10 y were comparable between groups. One-y survival improved from 70% in the early eras to 80% in the current era (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.41-0.97; P = 0.034). After adjustment for sex, age, and mechanical circulatory support, time-related improvement in survival was observed only in patients without CC (HR, 0.54; 95% CI, 0.32-0.91; P = 0.019) but not in those with CC (HR, 0.99; 95% CI, 0.36-2.73; P = 0.98). Causes of death were similar between patients with CC and the other etiological subgroups. Conclusions. Posttransplant survival is comparable between patients with CC, nonischemic cardiomyopathy, and ischemic cardiomyopathy. Although survival has improved significantly over years for most HT recipients, it has remained unchanged for those with Chagas disease. These trends underscore the importance of scientific research, policy discussions and a collaborative registry of heart transplantation in Chagas cardiomyopathy.